We are live on ! Find out more
TEVA icon

Teva Pharmaceuticals
TEVA

557 hedge funds and large institutions have $13.7B invested in Teva Pharmaceuticals in 2018 Q3 according to their latest regulatory filings, with 79 funds opening new positions, 172 increasing their positions, 170 reducing their positions, and 59 closing their positions.

New
Increased
Maintained
Reduced
Closed

34% more first-time investments, than exits

New positions opened: 79 | Existing positions closed: 59

3% more funds holding

Funds holding: 540 → 557 (+17)

1% more repeat investments, than reductions

Existing positions increased: 172 | Existing positions reduced: 170

5% less call options, than puts

Call options by funds: $596M | Put options by funds: $625M

2.94% less ownership

Funds ownership: 65.51% → 62.56% (-2.9%)

13% less funds holding in top 10

Funds holding in top 10: 16 → 14 (-2)

15% less capital invested

Capital invested by funds: $16.2B → $13.7B (-$2.5B)

Holders
557
Holders Change
+17
Holders Change %
+3.15%
% of All Funds
12.73%
Holding in Top 10
14
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-12.5%
% of All Funds
0.32%
New
79
Increased
172
Reduced
170
Closed
59
Calls
$596M
Puts
$625M
Net Calls
-$29M
Net Calls Change
+$122M

Top Buyers

Rank Fund Capital Flow
1
Wellington Management Group
Wellington Management Group
Massachusetts
+$197M
2
Capital World Investors
Capital World Investors
California
+$112M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$91M
4
BMO
Beck Mack & Oliver
New York
+$69.5M
5
AllianceBernstein
AllianceBernstein
Tennessee
+$53.2M

Top Sellers

Rank Fund Capital Flow
1
NC
Northern Cross
Massachusetts
-$502M
2
HCM
Highfields Capital Management
Massachusetts
-$303M
3
PC
PointState Capital
New York
-$162M
4
Franklin Resources
Franklin Resources
California
-$132M
5
Millennium Management
Millennium Management
New York
-$113M
Name Holding Trade Value Shares
Change 		Change in
Stake
HWA
526
Heritage Wealth Advisors
Virginia
$3K +$3.25K +140 New
TPWA
527
TRUE Private Wealth Advisors
Oregon
$2.33K +$2.51K +108 New
FMII
528
Farmers & Merchants Investments Inc
Nebraska
$2K -$3.48K -150 -60%
CT
529
Clearstead Trust
Maine
$2K – – –
EWM
530
Endurance Wealth Management
Rhode Island
$2K – – –
GWS
531
Glassman Wealth Services
Virginia
$2K – – –
MCM
532
Manchester Capital Management
Vermont
$2K – – –
MWM
533
Mascoma Wealth Management
New Hampshire
$2K – – –
NCM
534
Nelson Capital Management
California
$2K – – –
NWM
535
Northwest Wealth Management
Iowa
$2K – – –
BAM
536
Bruderman Asset Management
New York
$2K +$975 +42 +68%
IF
537
Ironwood Financial
Arizona
$2K +$2.32K +100 New
PFGIA
538
Patriot Financial Group Insurance Agency
Massachusetts
$2K +$2.35K +101 New
BA
539
Ballew Advisors
Mississippi
$2K +$2.55K +110 New
GEA
540
Glen Eagle Advisors
New Jersey
$1.31K +$1.42K +61 New
AIM
541
Advantage Investment Management
Iowa
$1K -$42.1K -1,814 -98%
1832 Asset Management
542
1832 Asset Management
Ontario, Canada
$1K – – –
LWA
543
Lowe Wealth Advisors
Maryland
$1K – – –
MFT
544
Moisand Fitzgerald Tamayo
Florida
$1K – – –
RWA
545
Ropes Wealth Advisors
Massachusetts
$1K – – –
SWMG
546
Signature Wealth Management Group
Georgia
$1K – – –
WF
547
WealthTrust Fairport
Ohio
$1K – – –
WA
548
WP Advisors
California
$1K – – –
AC
549
Avestar Capital
New York
$1K +$255 +11 +10%
WWM
550
Willingdon Wealth Management
North Carolina
$1K +$766 +33 New
20 21
22
23 24

TEVA Hedge Fund Activity: Q3 2018 in Review

557 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in Teva Pharmaceuticals (TEVA) for Q3 2018, worth a combined $13.7B — down 15% from $16.2B a quarter earlier.

Buyers outnumbered sellers: 79 funds opened new TEVA positions and 59 closed out — a net gain of 20 holders — while 172 added to existing stakes and 170 trimmed.

The largest buyer was Wellington Management Group, adding an estimated $197M. The largest seller was Northern Cross, cutting an estimated $502M.

  • 557 institutional investors held Teva Pharmaceuticals (TEVA) as of Q3 2018, up from 540 in Q2 2018.
  • Funds reported $13.7B of Teva Pharmaceuticals stock for Q3 2018, down 15% quarter-over-quarter.
  • 79 funds opened new Teva Pharmaceuticals positions in Q3 2018 and 59 closed out, a net change of +20 holders.
  • The largest Teva Pharmaceuticals buyer in Q3 2018 was Wellington Management Group, an estimated $197M added.
  • The largest Teva Pharmaceuticals seller in Q3 2018 was Northern Cross, an estimated $502M sold.

Based on aggregated 13F filings for Q3 2018.